Belzutifan Outperforms Everolimus in Previously Treated, Advanced RCC
Belzutifan improved outcomes over everolimus in a phase 3 trial of patients with previously treated, advanced clear cell RCC.
Source: renalandurologynews.com
Page 36 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Merck Sharp Today - Breaking & Trending Today
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438--...
Source: marketscreener.com
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet...
Source: prnewswire.com
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with...
Source: marketscreener.com
Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript
Operator: [Started Abruptly] … Merck & Co. Q3 Sales and Earnings Conference Call.
Source: insidermonkey.com